2018
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.Peer-Reviewed Original ResearchConceptsPD-1 axis inhibitorsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerInhibitor therapyLocal therapyLymph nodesLung cancerSurvival rateSolid Tumors v1.1Response Evaluation CriteriaSite of diseaseProgression of diseaseProgressive diseaseClinical patternLN metastasisSuch patientsClinical featuresMedian timeRadiographic featuresTumor regressionProlonged benefitPatientsTherapyResponse criteria
2017
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology 2017, 3: 256-259. PMID: 27541827, PMCID: PMC5491359, DOI: 10.1001/jamaoncol.2016.3015.Peer-Reviewed Original ResearchPD-L1 expressionPD-L1Tissue microarrayImmunohistochemical analysisCell death 1 ligand 1PD-1 axis inhibitorsDeath 1 ligand 1Quantitative immunofluorescenceCell linesPredictive diagnostic testsTumor tissue coresPD-L1 proteinPrediction of responseYale Pathology archivesLung cancerClinical utilityPathology archivesDiagnostic testsMonoclonal antibodiesAntibodiesTissue controlsProtein levelsTissue coresLigand 1Concordant results